Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.390 +0.030 (+2.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Macrogenics
Via Benzinga
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market... 
Via Benzinga
7 Analysts Have This to Say About Macrogenics
Via Benzinga
Expert Ratings for Macrogenics
Via Benzinga
What 7 Analyst Ratings Have To Say About Macrogenics
Via Benzinga
Where Macrogenics Stands With Analysts
Via Benzinga
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
From MacroGenics, Inc.
Via GlobeNewswire
$5 Million Bet On IAC? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday. 
Via Benzinga
Why Shares of MacroGenics Were Dropping Tuesday
Profit-taking and an analyst downgrade affected the stock's price. 
Via The Motley Fool
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Burlington shares fell 0.1% to... 
Via Benzinga
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
Dow Jumps Over 300 Points; S&P 500 Rises 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
Crude Oil Surges 2%; Best Buy Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 250 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel... 
Via Benzinga
US Stocks Open Higher As Dow Surges 250 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Tuesday. 
Via Benzinga
First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles
Via Benzinga
Gap, Palo Alto Networks And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
From MacroGenics, Inc.
Via GlobeNewswire
Why MacroGenics Stock Crushed the Market on Monday
Positive momentum continues for the cancer specialist in the wake of its latest earnings report. 
Via The Motley Fool
MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences
BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares... 
Via Benzinga
360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock
One indicator of where a company’s stock might be going in the future can be understood by what insiders may be thinking of the Company’s current stock price and near-term future outlook. Insiders are... 
Via Benzinga
Why MacroGenics Stock Popped Again Today
Investors and analysts alike are getting more bullish on the company in the wake of its third-quarter results. 
Via The Motley Fool
Why MacroGenics Stock Blasted Higher Today
A quarter that was far better than expected gets investors excited about the biotech at the end of the week. 
Via The Motley Fool
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback